Key stats
About LEGAL & GENERAL UCITS ETF PLC L&G PHARMA BREAKTHROUGH GO UCITS ETF GBP
Home page
Inception date
Jan 23, 2018
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
LGIM Managers (Europe) Ltd.
ISIN
IE00BF0H7608
The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.95%
Health Technology94.88%
Finance3.09%
Process Industries1.98%
Bonds, Cash & Other0.05%
Cash0.05%
Stock breakdown by region
North America51.60%
Europe25.88%
Asia20.44%
Oceania2.08%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Symbol
Assets
Symbol
Assets
X
Xeris Biopharma Holdings, Inc.XERS
5.72%
P
Pharma Mar SAPHM
5.70%
9
InnoCare Pharma Ltd.9969
4.60%
O
BeiGene Ltd Sponsored ADRONC
3.63%
J
Jazz Pharmaceuticals Public Limited CompanyJAZZ
3.47%
B
Bristol-Myers Squibb CompanyBMY
3.28%
C
Catalyst Pharmaceuticals, Inc.CPRX
3.12%
R
Royalty Pharma Plc Class ARPRX
3.09%
A
argenx SE Sponsored ADRARGX
2.99%
4
Nippon Shinyaku Co., Ltd.4516
2.94%
Top 10 weight38.52%
38 total holdings